文献速递慢性肾脏病

贝特类药物与慢性肾脏病患者心血管结局风险

Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

贝特类药物使用与MACE风险降低显著相关(OR 0.84;95%CI 0.75-0.94),尤其当前使用(OR 0.81;95%CI 0.68-0.97)和近期使用(OR 0.65;95%CI 0.48-0.90);培马贝特使用与MACE风险降低显著相关(OR 0.73;95%CI 0.528-0.997),而苯扎贝特或非诺贝特无显著关联。

要点

  • CKD患者中贝特类药物使用与MACE风险降低显著相关(OR 0.84;95%CI 0.75-0.94)。
  • 当前使用(OR 0.81;95%CI 0.68-0.97)和近期使用(OR 0.65;95%CI 0.48-0.90)均与MACE风险降低显著相关。
  • 培马贝特使用与MACE风险降低显著相关(OR 0.73;95%CI 0.528-0.997),苯扎贝特或非诺贝特无显著关联。

核心结论

  • 近期和当前贝特类药物使用,尤其是培马贝特使用,与CKD患者MACE风险降低相关。
  • 这提示持续贝特类治疗可能获益,培马贝特可能优于其他贝特类药物,但需在不同人群中进一步研究确认可推广性。

研究设计与样本

  • 病例为发生MACE的CKD患者,按年龄、性别、队列进入日历年及CKD分期与对照匹配。
  • 贝特类暴露时机分为当前、近期或过去使用;采用条件logistic回归分析贝特类使用与MACE风险的关联。

主要发现

  • 研究期间贝特类药物使用例数:病例组556例(3.5%)vs 对照组1109例(3.5%)。
  • 贝特类药物使用与MACE风险降低显著相关(OR 0.84;95%CI 0.75-0.94)。
  • 当前使用与MACE风险降低显著相关(OR 0.81;95%CI 0.68-0.97)。
  • 近期使用与MACE风险降低显著相关(OR 0.65;95%CI 0.48-0.90)。
  • 培马贝特使用与MACE风险降低显著相关(OR 0.73;95%CI 0.528-0.997),苯扎贝特或非诺贝特使用与MACE风险无显著关联。

临床怎么用

  • 原文结论提示近期和当前贝特类药物使用,尤其是培马贝特,与CKD患者MACE风险降低相关,但需在不同人群中进一步研究确认可推广性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The high risk of major adverse cardiovascular events (MACE) in patients with chronic kidney disease (CKD) has been well described. However, the efficacy of fibrates on the risk of MACE in patients with CKD remains unclear. METHODS: We conducted a nested case-control study using data from a large administrative database that included more than 1.5 million Japanese patients. We defined cases as CKD patients with incidences of MACE and matched them with controls based on age, sex, calendar year of cohort entry and CKD stage. Fibrate exposure timing was categorized as current, recent or past. A conditional logistic regression analysis was used to investigate the association between fibrate use and the risk of MACE. RESULTS: Our study included 47 490 patients with CKD, with 15 830 MACE identified during a median follow-up of 9.4 months. The numbers of fibrates used during the study period were 556 (3.5%) in the case group and 1109 (3.5%) in the control group. Fibrate use was significantly associated with a decreased risk of MACE [odds ratio (OR) 0.84; 95% confidence interval (CI) 0.75-0.94], particularly for current (OR 0.81; 95% CI 0.68-0.97) and recent use (OR 0.65; 95% CI 0.48-0.90). Regarding the class effect of fibrates, pemafibrate use, but not bezafibrate or fenofibrate use, was significantly associated with a decreased risk of MACE (OR 0.73; 95% CI 0.528-0.997). CONCLUSION: Recent and current fibrate use, especially pemafibrate use, was associated with a reduced risk of MACE in patients with CKD. This suggests the potential benefits of continuous fibrate therapy and the possible superiority of pemafibrate over other fibrates. However, further investigations in different populations are required to confirm the generalizability of these findings.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Goto H, Iseri K, Hida N, et al. Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2024. PMID: 38012115. doi:10.1093/ndt/gfad248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。